drugset / Trial / NCT05345717

Novel Desensitization Kidney Transplantation

NCT05345717

Phase 1/2 Completed 5 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

This proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.

Timeline

Start
2022-05-01
Primary completion
2025-09-12
Completion
2025-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Belatacept Protein / enzyme biologic